Adrenal Insufficiency (AI) and Congenital Adrenal Hyperplasia (CAH) |
|
|
Glucocorticosteroid |
Hydrocortisone |
2 AIH + 2 CAG patients |
24-hour infusion regimen of HC that mimics circadian rhythms of cortisol levels can restore circulating cortisol rhythms, restore levels of ACTH, and reduce levels of plasma 17-OHP. |
24-h |
Merza, Rostami-Hodjegan et al. 2006 |
|
|
AI patients |
24-h sub-cutaneous HC administration on restoring cortisol, ACTH, and 17-OH rhythms as well as increasing nocturnal growth hormone and insulin growth factor levels in AI patients |
24-h |
Lovas and Husebye 2007; Bjornsdottir, Oksnes et al. 2015
|
Type I Diabetes Mellitus |
|
|
|
|
Hormone - Insulin Analogue |
Insulin |
Open, randomized, cross-over design; 14 patients who experience evening hypoglycemia |
Nighttime subcuntaneous continuous injections seem to be more effective at hypoglycemic control. |
Continous nighttime |
Kanc, Janssen et al. 1998 |
|
Insulin Ultratard |
9 Patients |
No significant difference in blood glucose levels at any point. |
No difference |
Edsberg, Dejgaard et al. 1987 |
|
|
Pediatric patients |
Continuous subcutaneous injections of insulin glargine reduced HbA1C levels and controlled pre-meal glucose levels better than multiple daily injections |
Continuous |
Doyle, Weinzimer et al. 2004 |
|
Insulin Glargine |
292 Patients |
Similar improvements were seen in morning, evening, or split dose groups. Split dosing results in weight gain. |
No difference |
Garg, Gottlieb et al. 2004 |
|
|
Patients whose HbA1C and glycemic levels were not controlled by single injections |
Split dosing was effective. |
Split dosing |
Albright, Desmond et al. 2004 |
|
|
18 Patients with poorly managed T1DM |
Transitioning from evening to morning administration, independent of dose, resulted in more favorable glucose control and lipid profile without affecting body weight. |
Morning |
Gradiser, Bilic-Curcic et al. 2015 |
|
Insulin Glargine + Lispro |
HbA1C levels and 24-hour glycemic control did not differ among groups administring insulin glargine in the morning, evening, or bedtime in conjunction with prandial insulin lispro; morning administration resulted in fewer nocturnal hypoglcemic episodes |
No differences; morning had added benefits |
Hamann, Matthaei et al. 2003 |
|
Lispro |
Randomized, cross-over study. 23 patients |
Administration of insulin glargine at lunch, dinner, or bedtime resulted in hypoglycemia at distinct timepoints after each injection; the night-time hyperglycemia after bedtime glargine injections was avoided with lunch or dinner injection schedules |
Ashwell, Gebbie et al. 2006 |
|
|
13 Patients |
More effective at evening and nocturnal glycemic control when the bedtime dose is greater than mealtime doses; Lower mealtime and higher bedtime doses might be most effective at evening glycemic control. |
Low mealtime, higher bedtime |
Ahmed, Mallias et al. 1998 |
|
Detemir + Aspart |
|
Combination therapy at mealtime provided equally effective glycemic control when administered as a morning/dinner or a morning/bedtime dose; however both regimens provided better glycemic control with no weight gain when compared to NPH morning/evening insulin regimen. |
Pieber, Draeger et al. 2005 |
Octapeptides |
Octreotide |
8 T1DM patients who experience evening hypoglycemia: 4 Females 4 Males |
Continuous subcuntaneous night injection is more effective at reducing hyperglycemia and growth hormone levels than single injections across the night. |
Continous nighttime |
Lunetta, Di Mauro et al. 1998 |
Type 2 Diabetes Mellitus |
|
|
|
|
Hormone |
Insulin |
100 Patients |
Higher morning:evening ratio seems to have greater safety and efficacy. |
Higher morning:evening |
Jung, Park et al. 2014 |
|
|
143 Patients |
For twice-daily doses of insulin, a higher morning:evening ratio might be more effective at managing glycemic levels. |
Higher morning:evening |
Lee, Lee et al. 2012, |
|
Insulin Glargine + Glimepiride |
624 patients |
Single daily dose was equally effective at glycemic control when given in the morning or evening. |
No difference |
Standl, Maxeiner et al. 2006 |
|
Insulin Glargine |
10 Patients |
Total insulin activity is similar between morning/evening doses. However, evening administration controls nocturnal EGP, lipolysis, and glucagon concentration more consistently, whereas morning administration has greater protection against nocturnal hypoglycemia. |
No difference |
Porcellati, Lucidi et al. 2015 |
Incretin Mimetics |
Lixisenatide |
680 T2DM patients with inadequate control of glucose levels by metformin |
Morning and evening injections similarly improve glucose control. |
No difference |
Ahren, Leguizamo Dimas et al. 2013 |
Meglitinide - Antidiabetic |
Repaglinide |
19 T2DM patients |
Mealtime dosing is more effective than morning/evening split dose. |
Mealtime |
Schmitz, Lund et al. 2002 |
Dipeptidyl Peptidase-4 Inhibitor |
Vildagliptin |
48 Patients |
Morning and evening dosing were equally effective at post-prandial and 24-h glucose control; however an evening dose was effective at reducing fasting plasma glucose. |
No difference, but evening has additional benefits |
He, Valencia et al. 2010 |
Gestational Diabetes Mellitus |
|
|
|
|
Hormone |
Insulin |
274 Females w/ Gestational Diabetes 118 Females with Pregestational Diabetes |
Insulin administered four times daily is more effective at glycemic control than twice daily. 30 mins before each meal and before bedtime. |
Four times/day |
Nachum, Ben-Shlomo et al. 1999 |
|
|
480 Females, >30 weeks pregnant. |
Four times daily. 30 mins before each meal, and before bed-time. |
Four times/day |
Saleem, Godman et al. 2016 |
Hypothyroidism |
|
|
|
|
|
Thyroid hormone |
Levothyroxine |
50 Patients |
Morning dose is more effective, but if evening dose is necessary for compliance, evening dose is acceptable. |
Morning, before mealtime |
Ala, Akha et al. 2015 |
|
|
12 Females |
Bedtime administration seems to improve thyroid hormone levels and reduced TSH levels. |
Bedtime |
Bolk, Visser et al. 2007, Banerjee, Hossain et al. 2018
|
|
|
105 Patients |
Bedtime administration improved thyroid hormone levels. |
Bedtime |
Bolk, Visser et al. 2010 |
|
|
152 Patients |
Morning and evening doses are equally effective |
No difference |
Rajput, Chatterjee et al. 2011 |
|
|
163 Children: 125 Females 38 Males |
No difference between bedtime and morning treatments. |
No difference |
Akin 2018 |
|
|
Older adults |
Clinical trial currently underway |
TBD |
Giassi, Piccoli et al. 2019 |
Fat-soluble vitamin |
Vitamin D3 |
13 Patients: 5 Females, 8 Males with secondary hyperparathyroidism in end-stage renal failure. |
Evening dose is more effective at managing hyperparathyroidism in patients with renal osteodystrophy. |
Evening |
Tsuruoka, Wakaumi et al. 2003 |
Osteoporosis |
|
|
|
|
|
Mineral |
Calcium |
14 patients |
Calcium-supplemented meals did not affect the levels of bone resorption or the circadian patterns of resorption in comparison to evening-only supplements |
No difference |
Aerssens, Declerck et al. 1999 |
|
|
26 early-menopausal females |
Split morning:evening dose of 500:1000 mg (Tot. 1500mg) |
Higher evening:morning |
Scopacasa, Need et al. 2002 |
|
|
19 post-menopausal females |
Single evening 1000 mg dose only suppressed bone resorption during the night. |
Split morning/evening |
Scopacasa, Horowitz et al. 1998 |
|
|
19 Females |
Split dosing improved daytime bone resorption but not nighttime resorption. |
Split morning/evening |
Scopacasa F, Need AG, Horowitz M, Wishart JM, Morris HA and Nordin BE (2000) Inhibition of bone resorption by divided-dose calcium supplementation in early postmenopausal women. Calcif Tissue Int
67:440–442. |
|
|
30 Females 21–34 y |
Split, morning, or 4 x daily doses showed no difference on bone resorption across the day, However parathyroid hormones were differently affected based on the size and timing of calcium dose, Need for longitudinal studies. |
No difference |
Kärkkäinen MU, Lamberg-Allardt CJ, Ahonen S and Välimäki M (2001) Does it make a difference how and when you take your calcium? The acute effects of calcium on calcium and bone metabolism. Am J Clin Nutr
74:335–342. |
Estrogen receptor modulator |
Raloxifene |
39 Post-menopausal females |
The only difference between morning/evening dose was the increase of plasminogen activator inhibitor (PAI)-1 with morning administration. Authors recommend evening administration. |
Evening |
Ando, Otoda et al. 2013 |
Parathyroid Hormone |
Teriparatide |
50 Females, post-menopausal |
Morning administration resulted in increase in lumbar spine BMD. |
Morning |
Michalska, Luchavova et al. 2012 |
|
Etidronate |
retrospective longitudinal study |
Dosing was similarly effective when taken as single doses across the day if the patient adhered to a 2 h fast before and after dosing |
No difference |
Cook, Blake et al. 2000 |
Cathepsin K Inhibitor |
ONO-5334 |
14 Females; single-blind crossover study |
Morning dose is more effective at reducing bone resorption than evening dose. |
Morning |
Eastell, Dijk et al. 2016 |
Hormone |
Salmon Calcitonin |
9 Females, Post-Menopausal |
Both 0800 h and 2100 h administration are effective with no obvious advantage to either. 0800 h versus 2100 h treatment transiently reduced bone resorption but did not effectively alter the circadian pattern of bone resorption. |
No difference |
Schlemmer, Ravn et al. 1997 |
|
|
81 Females between 40–70 y/o |
Pre-dinner (1700 h) administration resulted in the greatest reduction in bone resorption, when compared to 0800 h or 2200 h administration. |
Evening |
Karsdal, Byrjalsen et al. 2008 |
Growth Hormone Deficiency |
|
|
|
|
Hormones |
Growth Hormone |
|
Evening administration of GH was more effective at restoration of normal hormone and metabolite circadian patterns. |
Evening |
Jorgensen, Moller et al. 1990 |
|
|
8 adult patients |
Compared to one dose at 1900 h, split dosing at 1900 h (2/3 dose) and 0800 h (1/3 dose), better matched normal physiological GH profile, increased serum IGF-1, and decreased serum IGFBP-1 while lowering non-esterified fatty acids. |
Split dose at 0800 h, 1900 h |
Laursen, Jorgensen et al. 1994 |
|
|
34 children |
No differences between morning, afternoon or evening administration, in growth, IGF-1, or GH-BP after 6 or 12 months of GH treatment |
No difference |
Zadik, Lieberman et al. 1993 |
Glucocorticoid |
Prednisolone |
8 Patients: 4 Females 4 Males |
Morning administration attenuates nocturnal growth hormone suppression, therefore potentially attenuating stunted growth. |
Morning |
Wolthers, Ramshanker et al. 2017 |
Turner Syndrome |
|
|
|
|
|
Hormone |
Estradiol |
9 girls with Turner Syndrome receiving GH injections |
Estradiol was more effective at managing insulin, glucagon, IGF-1 levels when administered in the evening compared to morning, but further studies are needed. |
Evening |
Naeraa, Gravholt et al. 2001 |
Other Endocrine Treatments |
|
|
|
|
Hormone Therapy |
Cyclo-Progynova Therapy |
62 patients |
No obvious difference in efficacy of morning/evening treatment. |
No difference |
Pongsatha, Chainual et al. 2005 |
Artifical Hormones |
Hydrocortisone |
6 females |
Morning and evening administration is equally effective. |
No difference |
Kiriwat and Fotherby 1983 |